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ABSTRACT The tumor suppressor protein, p53, and the oncoprotein, Akt, are involved in a cross talk that could be at the core
of a cell’s control machinery for switching between survival and death. This cross talk is a combination of reciprocally
antagonistic pathways emanating from p53 and Akt, and also involves another tumor suppressor gene, PTEN, and another
oncogene, Mdm2; such a connected network of cancer-relevant genes must be signiﬁcant and demands a critical study. The
p53-Akt network is shown in this report to possess the potential to exhibit bistability, a phenomenon in which two stable steady
states of the system coexist for a ﬁxed set of control parameter values. A hierarchy of qualitative networks and abstract kinetic
models are analyzed and simulated on a computer to demonstrate the robustness of the bistable behavior, which, as argued in
this study, is a likely candidate mechanism for a cellular survival-death switch. The analysis applies to cells that are neither p53-
null nor Akt-null. The models presented here offer experimental predictions on the identity of control parameters of apoptotic
thresholds and on network perturbations (including DNA damage and Akt inhibition) that are sufﬁcient to generate switching
between pro-survival and pro-death cellular states.
INTRODUCTION
The tumor suppressor protein p53 is often referred to as the
‘‘guardian of the genome’’ because of its key role in in-
ducing cells to die when, for example, their DNA is irrep-
arably damaged. This role is implemented by promoting the
cell death program, called apoptosis, through mechanisms
that can be both dependent and independent of p53’s tran-
scriptional activity. At least half of known human cancers is
associated with p53 gene mutations, and the majority of the
remaining half involves malfunctions of the pathways reg-
ulating the protein’s activities (for reviews, see (1–4)). In
both mutated and wild-type cases, p53 is prevented from
causing apoptosis of cancer cells.
The serine-threonine kinase Akt, on the other hand, pro-
motes cell survival by inhibiting pro-apoptotic proteins (such
as Bad and Caspase-9) through phosphorylation (for
reviews, see (5–7)). Thus, p53 and Akt inﬂuence the process
of apoptosis in opposite ways. Recent results summarized in
the next section indicate that there are cross talks between
p53 and Akt involving gene transcription as well as post-
translational protein and membrane lipid modiﬁcations. In
this study, we investigate the cross talk that is characterized
as a positive feedback loop between p53 and Akt. This loop,
which also involves PTEN and Mdm2, can also be described
as a mutual antagonism between an oncoprotein, Akt, and a
tumor suppressor protein, p53 (8,9). The functional classi-
ﬁcation of PTEN as a tumor-suppressor protein (10–12) and
Mdm2 as an oncoprotein (13,14) further underlines the sig-
niﬁcance of studying the p53-Akt cross talk. Our goal in this
article is to analyze the regulatory network linking p53 and
Akt to gain insight on the control system of a cell’s decision
to survive or die. We will show that such a p53-Akt cell
survival-death switch can be sharp and robust.
There are many reported experimental observations sug-
gesting the possible existence of a cell survival-death switch
involving p53 and Akt (e.g., see (9,15,16)). Experimentally,
demonstrating the sharpness of such a switch would be
difﬁcult using a population of cells. The predictions of the
models we analyze below are relevant at the single-cell level,
and therefore experiments such as those carried out by Nair
et al. (15)—in which single-cell decisions between apoptosis
and survival were shown—would be required to validate our
models’ predictions. Interestingly, Nair et al.’s (15) results
suggest a bistable behavior of the system. Bistability means
the coexistence of two stable steady states with one unstable
state in between (17). Ultimately, our interest in understand-
ing the control of a survival-death switch is linked to the goal
of selectively inducing cancer cells to die while keeping
normal cells alive; the intricacies of this selective control are
expected to be understood by detailed studies of functional
networks orchestrating these cellular decisions. The analysis
of the p53-Akt network presented here aims to contribute to
this goal.
Admittedly, the p53-Akt network analyzed in this report is
merely a part of a more elaborate control system deciding
between cell survival and death. Furthermore, our results
would apply only to cells that are not null for either p53 or
Akt. The analysis we provide, however, could shed light on
the essential control principles and parameters of the switch.
A special feature of our method of analysis is the ability of
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generating valid conclusions on steady-state stability based
on network structure alone, and despite the lack of quantita-
tive data. Model predictions that can be veriﬁed experimen-
tally are discussed, including apoptotic thresholds and network
perturbations due to DNA damage and Akt inhibition.
EXPERIMENTAL BASES OF THE P53-AKT
MODEL NETWORKS
The complexity of p53 regulation is depicted in a recent
review by Harris and Levine (8), which focuses on the many
positive and negative feedback loops in the regulatory net-
works. Two of these loops are shown in Fig. 1. One is the
important negative feedback loop between Mdm2 and p53.
Mdm2 inhibits p53 using at least two mechanisms, namely,
by ubiquitination of p53 leading to proteosomal degradation,
and by blocking a transactivation domain of p53 (11 and 12).
On the other hand, expression of the mdm2 gene is induced
by p53. This negative feedback loop between p53 and Mdm2
has been cited as a reason for the observed oscillations in p53
activity (18 and 19). Although interesting, we do not explore
these oscillations in this report.
The link between p53 and Akt involves PIP3 (phospha-
tidyl inositol-3,4,5-trisphosphate) and PTEN (phosphatase
and tensin homolog) as shown in Fig. 1. PIP3 is required for
the recruitment of Akt to the plasma membrane where Akt
gets phosphorylated and activated. One way by which p53 in-
hibits production of PIP3 indirectly is by inducing the ex-
pression of the lipid phosphatase PTEN (reviewed in Harris
and Levine (8)). Another way is by repressing the catalytic
subunit of PI3K (phosphatidylinositol 3-kinase), the enzyme
that catalyzes the formation of PIP3 (16). Akt phosphory-
lates Mdm2 (arrow from Akt to Mdm2 in Fig. 1), causing
the latter to translocate to the nucleus where it inhibits p53
(20).
As shown in Fig. 1, a positive feedback loop (p53-Akt-
Mdm2-p53) and a negative loop (p53-Mdm2-p53) are
coupled via the Mdm2-p53 interaction. Mayo and Donner
(12) suggested an interesting interpretation of this coupling
based on a report that the p53-induced transcriptional ac-
tivation of Mdm2 precedes that of PTEN (21). According to
this interpretation, the p53-Mdm2 negative feedback loop
autoregulates the increase in p53 and delays p53-induced
apoptosis to allow cells with DNA that are not irreversibly
damaged or mutated to survive. A subsequent p53-induced
expression of PTEN triggers the p53-PTEN ‘‘ampliﬁcation
loop’’, which then suppresses the cell survival machinery;
it is then suggested that this suppression is obligate for
p53 apoptotic activity (12).
METHODS
The major steps in extracting model networks and their analyses are as
follows. The literature was reviewed to integrate experimental information
available on p53 and Akt pathways (see preceding section). Many of the
interactions or steps in the pathways can be described as ‘‘qualitative’’ in the
sense that no deﬁnitive mechanism or kinetic expressions and parameters
have been measured; nevertheless, they contain information on how a
molecular species affect the activity of a particular molecule or the rate of a
reaction. Thus, the ﬁrst step in the modeling process is to establish the
connectivity (topology) of the qualitative network (to be referred to as qNET
below), which contains ‘‘arrows’’ and ‘‘hammerheads’’ to indicate
‘‘activatory’’ and ‘‘inhibitory’’ interactions, respectively. Examples of
qNETs are given in Fig. 2. A brief summary of qNET analysis is given in the
appendix of the article by Aguda and Algar (22), where it was shown that
only cycles in a qNET graph determine local stability of a given steady state.
This is the motivation why the qNET models in Fig. 2 are only those that
contain cycles that are destabilizing (i.e., they could generate unstable steady
states). It is these destabilizing cycles that are taken as prime candidates for
switching dynamics in the network; in other words, instability of a steady
state means that its perturbation leads to switching to another state.
The second step in the modeling process is to use available mechanistic
information and encode them into abstract kinetic models. These models
are referred to as ‘‘abstract’’ in the sense that the essential qualitative
dynamics are captured by simple mathematical functions. For example, the
qualitative information that ‘‘DNA damage stabilizes p53’’ can be translated
as ‘‘d[p53]/dt ¼ (synthesis rate)  (decay rate)/(1 1 [DNAdamage])’’. The
functional form of the second term on the right-hand side of this equation
represents the idea that if the level of DNA damage increases, then the rate of
p53 decay decreases. Details of the abstract kinetic models are given in the
Appendix.
One of the key questions asked in this work is how robust the switching
mechanisms predicted by the models are. The approach used to answer this
question is to consider the hierarchy of models shown in Fig. 2, starting from
the simplest interaction between p53 and Akt (mutual antagonism) to
networks with increasing mechanistic details. As shown in Fig. 2, each
qNET model is associated with an abstract kinetic model. The dynamics of
these abstract kinetic models are represented by deterministic ordinary
differential equations. The differential equations are integrated using a
modiﬁed Rosenbrock formula of order 2, which is implemented in the
MATLAB (The MathWorks, Natick, MA) platform (version 6.5, Release
13). To determine the steady states of the kinetic models, the right-hand sides
of the differential equations are all set to zero and the corresponding systems
of nonlinear algebraic equations were solved numerically using Maple
(version 7.0). The steady states as functions of certain parameters are referred
to as steady-state bifurcation diagrams (shown in the right-most column of
Fig. 2). The local stability of the steady states is determined using standard
linear stability analysis, which involves determining the eigenvalues of the
associated Jacobian matrices. In addition, the sensitivity of the system’s
FIGURE 1 Various positive and negative feedback loops involving the
p53-Mdm2 regulatory network. Interactions are shown as arrows (to mean
‘‘activate’’) and hammerheads (to mean ‘‘inhibit’’), and these are not
necessarily direct. See text for more details.
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behavior to perturbations of parameters was investigated, ﬁrst, by a brute-force
method of varying parameters and, secondly, by mapping phase diagrams in
parameter space. Different regions in these diagrams represent different
numbers of steady states. The Appendix gives all the dynamical equations and
parameters used in the models. The SupplementaryMaterial describes in more
detail our comprehensive exploration of biologically reasonable ranges of
parameter values that led to the choice of model parameters.
RESULTS AND DISCUSSION
Hierarchy of models and robustness of bistability
Several models of increasing degree of mechanistic details
have been analyzed to demonstrate the robustness of the
switching behavior expected from the positive feedback loop
between p53 and Akt. The simplest of these models is Model
Q1 in Fig. 2. This model predicts a situation where either p53
is ‘‘on’’ and Akt is ‘‘off’’ or vice versa, depending on which
protein happens to have the upper hand. As shown in Fig. 1,
p53 antagonizes Akt by inhibiting the production of PIP3
either by inducing expression of PTEN or inhibiting PI3K;
these two ways of inhibiting PIP3 can be represented by two
abstract kinetic models: one is shown in the ﬁrst row and
second column of Fig. 2, where p53 directly inhibits the
formation of active Akt* (corresponding to the inhibition of
PI3K); the other means of inhibiting PIP3 (not shown)
corresponds to p53’s transcriptional induction of PTEN,
which deactivates Akt*. We found that simulations using
both PIP3-inhibition models generate similar steady-state
bifurcation diagrams; the diagram shown in the ﬁrst row
and last column of Fig. 2 is for the ﬁrst case. The parameters
used for the simulation of Model Q1 are provided in the
Appendix. Note that the parameter being varied (the abscissa)
is the total Akt protein level (Akttot). Akttot can be assumed
constant within the timescale of the phosphorylation and
dephosphorylation processes involved in the activation of
Akt; these processes occur relatively faster than the transcrip-
tional, translational, and degradation processes involving the
Akt protein. This assumption is also supported by experimen-
tal data that show the amount of Akttot remaining relatively
constant after irradiation or treatment with chemotherapeutic
drugs even when the amount of active Akt* decreased dras-
tically (9,23).
The kinetic equations for Model Q1 are given below as
examples of the differential equations used to describe the
FIGURE 2 A hierarchy of models
used to illustrate the robustness of the
bistable behavior of the p53-Akt net-
work. First column shows the qualita-
tive network of the models, second
column gives corresponding abstract
kinetic models, and the last column dis-
plays the steady states of p53 (shaded
curve) and of active Akt* (solid) as
functions of a control parameter (total
Akt, Akttot). Details of the abstract ki-
netic models are given in the Appendix.
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behavior of the model networks (equations for the other
models are given in the Appendix):
d½p53=dt ¼ v0  v2 (1)
d½Akt=dt ¼ v1  vm1; (2)
where v0 ¼ k0 (a constant), v1 ¼ k1[Akt]/[(j1 1 [Akt])(1 1
[p53])], vm1 ¼ k1[Akt*]/(jm1 1 [Akt*]), v2 ¼ k2[Akt*]
[p53]/(jm2 1 p53) 1 kd[p53], and [Akt] ¼ [Akttot]  [Akt*].
The rate (v0) of synthesis and activation of p53 is assumed
to have a constant value of k0. The rate (v1) of activation of
Akt to Akt* is assumed to have a Michaelis-Menten type
expression and is inversely proportional to [p53] to account
for the inhibition of this step by p53. The rate (vm1) of
deactivation of Akt* is of the Michaelis-Menten type. The
rate (v2) of p53 decay includes both Akt-dependent and
Akt-independent degradation.
The steady-state bifurcation diagram for Model Q1 is
shown in the ﬁrst row and last column of Fig. 2. The solid
curve shows how the steady states of Akt* change with
increasing [Akttot]. The shaded curve corresponds to p53
steady states. Generally, as steady-state [Akt*] increases, the
steady-state [p53] decreases, and vice versa, as expected. A
nonintuitive feature, however, is the existence of a range of
[Akttot], where three steady states of Akt* and of p53 coexist.
This range is referred to as the bistable range. For either p53
or Akt*, the middle steady states in the bistable range
represents unstable ones, whereas the other two outer states
are stable. What is the biological signiﬁcance of the existence
of a bistable range for [Akttot]? The presence of a bistable
range deﬁnes threshold points for the control parameter
[Akttot] (corresponding the left and right knees of the curves)
where irrevocable decisions are made. Note that between
these two knees (i.e., within the bistable range) is a range of
parameter values where perturbations that are sufﬁcient to
cross the middle unstable state will switch the system from
one stable steady state to the other.
Model Q2 in Fig. 2 includes an important ingredient in the
p53 regulatory network, namely, Mdm2. The qNET diagram
for this model is identical to the one suggested by Gottlieb
et al. (9). A linear stability analysis of this qNET shows that
it is always unstable (one eigenvalue of the Jacobian matrix
has a positive real part), and that this instability is of the
‘‘saddle point’’ type and could therefore exhibit a switching
behavior (note that Model Q1 is also of the saddle point
type.). Also, one can show that the instability is due only to
the positive three-cycle composed of the sequence p53-Akt-
Mdm2-p53. The negative two-cycle between p53 and Mdm2
is not a source of instability (it is marginally stable, i.e., of
the ‘‘neutral’’ kind). An abstract kinetic model implementa-
tion of Model Q2 is shown in Fig. 2. The kinetic equations
and parameters are given in the Appendix. The steady-state
bifurcation diagram is shown in the last column of the second
row of Fig. 2. This diagram proves that there can also be a
range of [Akttot] where bistability occurs; thus, the bistable
property of the death-survival switch is robust against the
additional participants (Mdm2 and Mdm2*) and interactions
in the network.
Finally, we consider Model Q3 in Fig. 2, which is a more
detailed network involving PTEN and PIP3. In the corre-
sponding abstract kinetic model, the p53-dependent tran-
scription of Mdm2 (rate v5 in the Appendix) and the
phosphorylation of Mdm2 by Akt* (rate v6 in the Appendix)
causing Mdm2 to translocate to the nucleus are taken into
account; furthermore, shuttling ofMdm2 out of the nucleus is
represented by rate vm6 in the Appendix. Note that PIP2 and
PIP3 are involved in cyclic phosphorylation-dephosphoryl-
ation processes. As shown by the steady-state bifurcation
diagram for Model Q3 (Fig. 2), a bistable range of [Akttot]
exists, showing once again the robustness of this property.
In the Supplementary Material, we demonstrate the ro-
bustness or conservation of the bistability phenomenon as
the model is simpliﬁed sequentially from Model Q3, to
Model Q2, and ﬁnally to Model Q1. The method of pa-
rameter sensitivity analysis is brute force and involves
varying the values of those parameters that have not been
measured directly in experiments. Parameter values in Model
Q3 that give rise to bistability are handed down to identical
steps found in Model Q2, and parameters in the latter model
that correspond to a group of steps in Model Q3 are made to
vary to show that bistability is conserved. A similar demon-
stration was carried out when Model Q2 was simpliﬁed to
Model Q1. Details can be found in the Appendix and Sup-
plementary Material.
To show the extent of bistable regions in parameter space,
phase diagrams can be plotted to illustrate how different
parameter values lead to either bistability or monostability.
Examples of such phase diagrams are given in Figs. 3, A–C.
The curves shown in Fig. 3 delineate, on the k1-k2 param-
eter plane, regions of bistability (three steady states) from
regions of monostability (one steady state), for three values
of km3.
Simulation of DNA damage
We have investigated the effects of DNA damage using all
the models given in Fig. 2 and found their responses to be
qualitatively similar; hence, the following discussion only
refers to results using Model Q1. As mentioned previously,
DNA damage is incorporated in the equation for d[p53]/dt in
Eq. 1 by dividing the rate of decay (v2) by (11 [DNAdamage])
to simulate the observation that p53 stabilization is associ-
ated with increased DNA damage. A set of simulations for
various levels of DNA damage is shown in Fig. 4. We also
have carried out simulations that account for the possibility
that the rate of p53 synthesis and activation (v0 in Eq. 1) in-
creases with increasing DNA damage; the results are qual-
itatively equivalent to those of Fig. 4 and are not reported
here.
As shown in Fig. 4, as the extent of DNA damage in-
creases, the middle curve of unstable steady states shifts
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down and lengthens in range. This downshift may be inter-
preted as the tendency to favor apoptosis over survival
because of a lowered threshold for switching to the upper
p53 stable states. The increase in the range of the bistable
region is signiﬁcant as we now explain. One can envisage a
scenario in which DNA damage leads to a sudden increase in
p53 with a concomitant decrease in Akt; for example, using
curve 1 in Fig. 4, the system ﬁnds itself in the upper stable
steady-state branch of the curve. But sustained growth factor
signaling would be expected to upregulate Akt (e.g., via the
Ras-PI3K pathway), causing a decrease in p53 activity down
to the right ‘‘knee’’ of the curve where it discontinuously
drops down to very low values, thereby entrenching the sur-
vival of the cell. If the DNA damage level increases (curves
2–3), the position of the right knee extends to the right cor-
responding to increasing Akttot threshold levels for shutting
off p53. Curve 4 demonstrates that there may be a level of
DNA damage at which the Akttot threshold extends to prac-
tically inﬁnity, which is the situation for an unsalvageable
cell (assuming that all points on the upper branch lead to
apoptosis) or, alternatively, a cell that is primed for apoptosis;
however, even for such primed cells, the model predicts that
there could be certain ﬁnite perturbations that cross the middle
unstable curve and shut off p53.
Another interesting prediction could be made regarding
the reverse of the scenario mentioned in the previous para-
graph: the model predicts that there are ﬁnite perturbations
that could switch the system from the low to the high p53
steady state. The kinetic models in Fig. 2 offer predictions on
how such a ﬁnite perturbation can be implemented. Fig. 5
shows a simulation of the effect of an inhibitor that binds
Akt* and effectively reduces the rate of p53 degradation.
The simulations in Fig. 5 show that there is a sharp threshold
value of the inhibitor of Akt* that enables the system to
switch to a higher p53 steady state. This could explain ob-
servations (23) that treatment of leukemia cells (HL60) with
inhibitors of Akt restored their sensitivity toward chemo-
therapeutic drugs. Similarly, since PI3K inhibitors indirectly
inhibit Akt activation, various cell lines such as acute myeloid
leukemia cells (24), HTLV-1-transformed cells (25), and
Ewing’s Sarcoma family of tumors (26) have been shown to
restore their sensitivity toward chemotherapeutic drugs after
incubation with PI3K inhibitors.
Predictions on apoptotic thresholds
Admittedly, there are several downstream events from p53
and Akt that are somehow integrated to give a net decision
FIGURE 3 Phase diagrams are generated for Model Q1 to map bistable
and monostable regions in parameter space. The parameters used are k1
(phosphorylation rate of Akt), k2 (Mdm2-dependent degradation rate of p53)
and km3 (dephosphorylation rate of Akt* induced by p53). For each plot, km3
is ﬁxed, whereas both k1 and k2 are varied. The curves represent the
boundaries between bistable (circled No. 3) and monostable (circled No. 1)
regions. The values of the other parameters (besides km3, k1, and k2) are
given in the Appendix.
FIGURE 4 Steady states of p53 as a function of Akttot for various extents
of DNA damage. Model Q1 was used in the computer simulations. See text
for details. Extent of DNA damage (arbitrary units) for curves 1–4 are 0,
0.01, 0.02, and 0.1, respectively.
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whether or not to activate the executioner caspases that trigger
apoptosis. For example, Akt inhibits Bad and caspase-9,
whereas p53 induces the expression of Bax, various caspases,
etc. (8); these proteins themselves involve complex regula-
tion. However, for modeling purposes, we will assume that
there exists a minimum p53 activity, called p*, and a maxi-
mum total amount of Akt, called k*, whose combination
would ultimately lead to apoptosis. Because of the p53-Akt
cross talk, the steady-state bifurcation curves in Fig. 2 would
provide the relationship between k* and p*. We refer to
(k*, p*) as the ‘‘apoptosis threshold’’ that leads to apoptosis.
Again, as our models do not consider pathways downstream
of either p53 or Akt, one may expect that the p53-Akt
threshold does not necessarily correspond to points on the
upper stable branch of p53 steady states or to points on the
middle branch of unstable steady states. One can envisage
experiments in which the initial conditions for [p53] and
[Akttot] are varied and then observe whether these conditions
ultimately lead to apoptosis. The predictions of our models
for such experiments are shown in Fig. 6. For various p53-
Akt threshold values indicated by the solid circle on the
steady-state curve, the shaded regions represent initial con-
ditions leading to apoptosis.
If the apoptotic threshold (solid circle) is between kL and
kR, then the shaded areas are qualitatively the same for cases
b–d. For cases c and d in Fig. 6, where the threshold is found
either in the middle or lower branch of steady states, any
initial condition above the middle unstable branch will be
repelled to the higher steady-state branch of p53. An in-
teresting conclusion is that any threshold located within the
middle branch will always give the identical shaded area
shown in case c; the apoptotic threshold for p53 in this case
will increase for increasing Akttot because of the positive
slope of the middle branch of the curve. This could explain
observations such as those reported by Hovelmann et al. (27)
that apoptotic thresholds increase with Akt. For case b,
where the threshold is on the uppermost branch of steady
states, not all points of the middle branch are apoptotic
threshold points. Case b can be distinguished experimentally
from cases c and d by the possibility of switching to a higher
p53 steady state in case b without causing apoptosis. Outside
the bistable regions (cases a and e), the apoptotic threshold
would apparently depend only on Akttot and not on p53.
CONCLUDING REMARKS
The most signiﬁcant among the experimental predictions of
our models is the existence of the robust phenomenon of
bistability in the p53-Akt network; the shaded areas in the
FIGURE 5 Perturbation of the p53-Akt network (Model Q1) using an
inhibitor X that binds active Akt*. Various levels of X were used (see inset)
to illustrate a discontinuous response of the system from a low to a high
steady state of p53, as a consequence of the bistability. Added to the kinetic
steps in Model Q1 are the binding reaction between X and Akt* and the
dissociation reaction of the (Akt*-X) complex with rates vb ¼ kb[X][Akt*]
and vb ¼ kb[Akt*-X], respectively. The initial concentration for each
species in the model is set to its steady-state value corresponding to the cell
survival state. The parameters values are: kb ¼ 1, kb ¼ 0.1, and others
are identical to those of Model Q1. Initial conditions are: p53 ¼ 0.248,
Akt* ¼ 0.0973, Akttot ¼ 0.1
FIGURE 6 Possible sets of initial conditions (shaded
areas) of total Akt and of p53 that lead to apoptosis for
various apoptotic thresholds indicated by the solid circle
with coordinates (k*, p*). Cases b–d give rise to quali-
tatively similar shaded areas that indicate the existence
of bistability.
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diagrams of cases b–d of Fig. 6, if shown experimentally,
would provide evidence for a bistable range. There are
several reasons why bistability is an important property of a
cellular switch between death and survival. First, if there
were no bistability, this putative switch will be at the mercy
of random concentration ﬂuctuations inside the cell. Second,
a bistable region ensures a range of parameters within which
the switch can be regulated, perhaps by ﬁnite (nonrandom)
external perturbations or by signals from other pathways that
impinge on the p53-Akt core network considered here.
Third, the apoptotic threshold no longer depends only on p53
but also on Akt as a consequence of the positive feedback
loop between these proteins. Thus, according to our models,
it is meaningless to specify a p53 apoptotic threshold without
mentioning an associated threshold value for Akt.
The middle unstable curve of steady states within the
bistable range usually sets the threshold between death and
survival (except case b in Fig. 6). Note that the middle
unstable p53 steady-state branch increases as Akttot increases;
in other words, within the bistable range, for a ﬁxed value of
Akttot and for a cell that is alive and has not been exposed to
stress, our results predict that there is a p53 threshold con-
centration (the middle unstable p53 steady state) above which
apoptosis is possible. Outside the bistable range and for Akttot
greater than the maximum limit (kR) of the bistable range (and
for apoptotic thresholds corresponding to cases a–d in Fig. 6),
the cell is resistant to apoptosis; for Akttot less than the mini-
mum of the bistable range (kL), our results show that the
system always goes to the high p53 steady state that is primed
for apoptosis (meaning that if the corresponding p53 steady
state has not reached the actual threshold to trigger apoptosis,
the system will only need a little bit more decrease in Akttot to
tip the system over to apoptosis).
The models we considered here ignored other known
details of the regulation of the activities of p53 and Akt. The
models can be extended by considering how the parameters
are linked to other pathways. The rate parameters k0 and kd
(found in all three models in this article) are the links of the
p53-Akt network to various growth factor signaling path-
ways and DNA damage signal transduction pathways (see
Harris and Levine (8) for a recent review). As a speciﬁc
example, Ras signaling induces activation of the p38 MAP
kinase, which, in turn, contributes to p53 activation and
stabilization (i.e., Ras signaling affects both k0 and kd). The
ATM kinase, which is activated in response to DNA damage,
phosphorylates both p53 (causing activation and stabiliza-
tion) and Mdm2 (leading to loss of enzyme activity and
degradation) (28); this p53 phosphorylation is equivalent to
either an increase in k0 and/or a decrease in kd, whereas the
Mdm2 phosphorylation corresponds to a decrease in k2
(Mdm2-dependent degradation of p53, via Akt indirectly).
An interesting future study (outside the scope of this article)
will also include the downstream pathways from p53 (e.g.,
the caspase cascade that triggers apoptosis) and from Akt
(e.g., the inhibition of pro-apoptotic proteins such as Bad and
Caspase-9). Modeling of the thresholds of apoptosis has
recently been reported (29–31), but none considered cross
talk between p53 and Akt.
APPENDIX
The dynamical equations and parameter values for Model Q3, Q2, and Q1
are given here. Below, [Akts] and [Mdm2s] are identical to [Akt*] and
[Mdm2*], respectively, in the text. The symbol ^ means exponentiation.
Model Q3
The rate expressions, differential equations, and parameter values (Table 1)
are given below.
v0 ¼ k0
v1 ¼ k13½PIP33½Akt=ðj11 ½AktÞ
vm1 ¼ km13½Akts=ðjm11 ½AktsÞ
v2 ¼ k23½Mdm2s3½p53=ðj21 ½p53Þ
v3 ¼ k33½p53^ n1=ðj3 n^11 ½p53^ n1Þ
v4 ¼ k43½PIP2=ðj41 ½PIP2Þ
vm4 ¼ km43½PTEN3½PIP3=ðjm41 ½PIP3Þ
v5 ¼ k53½p53^ n2=ðj5 n^21 ½p53^ n2Þ
v6 ¼ k63½Akts3½Mdm2=ðj61 ½Mdm2Þ
vm6 ¼ km63½Mdm2s=ðjm61 ½Mdm2sÞ
d½p53=dt ¼ v0  v2  kd3½p53
d½Akts=dt ¼ v1  vm1
d½PIP3=dt ¼ v4  vm4
d½PTEN=dt ¼ pPTEN1 v3  dPTEN  ½PTEN
d½Mdm2s=dt ¼ v6  vm6  dMdm2s3½Mdm2s
d½Mdm2=dt ¼ pMdm21v5v61 vm6 dMdm23½Mdm2
½Akttot ¼ ½Akt1 ½Akts
½PIPtot ¼ ½PIP21 ½PIP3:
Model Q2
The rate expressions, differential equations, and parameter values (Table 2)
are given below.
v0 ¼ k0
v1 ¼ k13½Akt=ðj11½AktÞ
vm1 ¼ km13½Akts=ðjm11½AktsÞ
v2 ¼ k23½Mdm2s3½p53=ðj21½p53Þ
vm3 ¼ km33½p533½Akts=ðjm31½AktsÞ
v4 ¼ k43½Mdm23½Aktsðj41½Mdm2Þ
vm4 ¼ km43½Mdm2s=ðjm41½Mdm2sÞ
v5 ¼ k53½p53^ n=ðj5 n^1½p53^ nÞ
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d½p53=dt ¼ v02 v22 kd  ½p53
d½Akts=dt ¼ v12 vm12 vm3
d½Mdm2sdt ¼ v42 vm42 dMdm2s  ½Mdm2s
d½Mdm2dt ¼ pMdm21 v52 v41 vm42 dMdm2  ½Mdm2
½Akttot ¼ ½Akt1½AKTs:
The step associated with this kinetic parameter is a simpliﬁcation of the
steps labeled v3, vm4, and v1 in Model Q3. This parameter is assigned arbitrary
values (but is varied in the sensitivity analysis described in the Supplementary
Material).
Model Q1
The rate expressions, differential equations, and parameter values (Table 3)
are given below.
v0 ¼ k0
v1 ¼ k13½Akt=ðj11½AktÞ
vm1 ¼ km13½Akts=ðjm11½AktsÞ
v2 ¼ k23½Akts  ½p53=ðj21½p53Þ
vm3 ¼ km33½p533½Akts=ðjm31½AktsÞ
d½p53=dt ¼ v02v22kd3½p53
d½Akts=dt ¼ v12 vm12 vm3
½Akttot ¼ ½Akt1½Akts:
The value of k2 in Model Q1 cannot be inferred or inherited directly from
its value from either Model Q3 or Q2, since the step corresponding to this
parameter is an abstraction of the pathway between p53 and Akt by removing
Mdm2. This parameter is assigned arbitrary values (but is varied in the
sensitivity analysis described in the Supplementary Material).
SUPPLEMENTARY MATERIAL
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TABLE 1 The 28 parameters used in the model simulations
for Model Q3; for details on the choice of model parameters,
see Supplementary Material
Rate constant Units Value Range References
k0 mM/min 0.1 0.005–0.2 32
kd min
1 0.05 0.02–0.2, 0.05 32, 20, 18
k1 min
1 20 20 39
j1 mM 0.1 0.1 39
km1 mM/min 0.2 0.0000297–2.92 34, 37
jm1 mM 0.1 0.1 39
k2 min
1 0.055 0.0184–0.092 32
j2 mM 0.1 0.03–0.3 32
pPTEN mM/min 0.001 Unknown
dPTEN min1 0.0054 0.0025–0.0083 42
k3 mM/min 0.006 0.006 21
j3 mM 2 .1 21
k4 mM/min 0.15 0.15 37
j4 mM 0.1 0.1 39
km4 min
1 73 42.1, 73 6 4.4 39, 40
jm4 mM 0.5 0.1–1 39, 42, 44
pMdm2 mM/min 0.018 ;0.018 32
dMdm2 min1 0.015 0.0028, 0.0347 32, 18
dMdm2s min1 0.015 0.0028, 0.0347 32, 18
k5 mM/min 0.024 0.024 32
j5 mM 1 ;1 32
k6 min
1 10 0.42–64.8 33–37, 39
j6 mM 0.3 0.00357–146 33–37, 39
km6 mM/min 0.2 0.0000297–2.92 34, 37
jm6 mM 0.1 0.00238–2.23 34–37, 39
n1 3 3 43
n2 3 3 43
[PIP]tot mM 1 Arbitrary
TABLE 2 The 20 parameters used in the model simulations
for Model Q2; for details on the choice of model parameters,
see Supplementary Material
Rate constant Units Value Remarks
k0 mM/min 0.1 As in Model Q3
kd min
1 0.05 As in Model Q3
k1 mM/min 0.15 Corresponds to k4 of Model Q3
j1 mM 0.1 As in Model Q3
km1 mM/min 0.2 As in Model Q3
jm1 mM 0.1 As in Model Q3
k2 min
1 0.055 As in Model Q3
j2 mM 0.1 As in Model Q3
km3 min
1 7.05 Arbitrary
jm3 mM 2 Similar to j3 in Model Q3
pMdm2 mM/min 0.018 As in Model Q3
dMdm2 min1 0.015 As in Model Q3
dMdm2s min1 0.015 As in Model Q3
k4 min
1 10 As in Model Q3
j4 mM 0.3 As in Model Q3
km4 mM/min 0.2 As in Model Q3
jm4 mM 0.1 As in Model Q3
k5 mM/min 0.024 As in Model Q3
j5 mM 1 As in Model Q3
n 3 As in Model Q3
TABLE 3 The 10 parameters used in the model simulations
for Model Q1; for details on the choice of model parameters,
see Supplementary Material
Rate constant Units Value Remarks
k0 mM/min 0.1 As in Model Q3
kd min
1 0.05 As in Model Q3
k1 mM/min 0.6 0.15 in Model Q2
j1 mM 0.1 As in Model Q3
km1 mM/min 0.2 As in Model Q3
jm1 mM 0.1 As in Model Q3
k2 min
1 0.4 Arbitrary
j2 mM 0.1 As in Model Q3
km3 min
1 7.05 As in Model Q2
jm3 mM 2 As in Model Q2
864 Wee and Aguda
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